France Next-Generation Sequencing (NGS) Services Market (2017-2022)
The France Next-Generation Sequencing (NGS) Services Market was valued at $62.7 Million in 2017 and projected to reach to $151.1 Million by 2022, representing a compound annual growth rate of 19.2%. France's NGS services market is poised for sustained growth through 2022 and beyond, driven by increasing healthcare investments in precision medicine and genomic research infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This expansion reflects France's increasing adoption of advanced genomic technologies across clinical diagnostics, research institutions, and pharmaceutical development.
- France's healthcare sector has prioritized precision medicine initiatives, driving demand for NGS services among hospitals, diagnostic laboratories, and academic research centers. The 19.2% compound annual growth rate (CAGR) positions France as a dynamic market within the European NGS landscape.
- France's investment in genomic infrastructure, coupled with growing awareness of personalized medicine applications, has accelerated service adoption across oncology, rare disease diagnosis, and infectious disease monitoring.
- The French government's support for genomic research and healthcare modernization has further catalyzed market expansion, attracting both domestic and international NGS service providers to establish operations within France. Looking toward 2022, France's NGS Services Market continues to benefit from technological advancements, declining sequencing costs, and regulatory frameworks supporting genomic testing integration into standard clinical practice.
- France's strategic positioning within Europe and its robust healthcare infrastructure position the country as a key growth hub for NGS service expansion..
Key Market Statistics
- CAGR (2017-2022) 19.2% CAGR
- Market Size, 2017 ~USD 62.7 Million
- Forecast, 2022 ~USD 151.1 Million
- Country France
France Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
France's NGS services market grew from $62.7 million in 2017 to $151.1 million by 2022, representing a 19.2% CAGR and demonstrating strong adoption of genomic sequencing technologies across the country.
Clinical Diagnostics Leadership :
French healthcare institutions are increasingly integrating NGS into clinical diagnostics for cancer genomics, rare disease identification, and personalized medicine, driving demand for specialized sequencing services.
Research & Pharma Investment :
France's robust pharmaceutical and research sectors are leveraging NGS for drug development, biomarker discovery, and clinical trials, positioning the country as a key hub for genomic innovation in Europe.
Outpacing Global Growth :
France's 19.2% CAGR slightly trails the global market's 21% growth rate, indicating competitive positioning while maintaining strong regional momentum in Western European genomics adoption.
France Next-Generation Sequencing (NGS) Services Market Dynamics
- The country's strong pharmaceutical sector and advanced research institutions are accelerating the adoption of next-generation sequencing across clinical diagnostics, oncology, and rare disease applications.
- Regulatory support for genomic medicine and growing reimbursement for NGS-based tests are expected to further expand market opportunities.
- French laboratories and diagnostic centers are investing in state-of-the-art sequencing platforms to meet rising demand from hospitals and research organizations, positioning France as a significant player in Europe's genomics market..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- France's NGS Services Market grew from $62.7M (2017) to $151.1M (2022), representing a 19.2% CAGR.
- France's precision medicine initiatives and government support have accelerated NGS adoption across clinical and research sectors.
- France's declining sequencing costs and regulatory frameworks have enabled broader integration of genomic testing into standard healthcare practice.
- France's strategic European position and robust healthcare infrastructure position it as a key growth hub for NGS service providers.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
France Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- French Healthcare Providers : Hospital networks and diagnostic centers need market data to justify NGS infrastructure investments, understand competitive positioning, and plan genomic medicine service expansion across France.
- Pharmaceutical & Biotech Companies : French and international pharma firms require France-specific NGS market insights to optimize clinical trial strategies, identify biomarker opportunities, and assess demand for sequencing-based drug development services.
- NGS Service Providers & Vendors : Sequencing platform manufacturers and service providers need detailed France market analysis to guide product localization, pricing strategies, and sales planning for the French healthcare and research sectors.
- Research Institutions & Universities : French academic and research organizations require market intelligence to secure funding, benchmark genomic capabilities, and align research initiatives with growing clinical and commercial NGS applications.
- Healthcare Investors & Consultants : Investment firms and management consultants need France-specific NGS market data to evaluate portfolio opportunities, assess sector growth potential, and advise clients on genomics market expansion strategies.
Key Companies in the France Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for France ($62.7M in 2017, $151.1M in 2022) with verified 19.2% CAGR to support investment decisions and competitive benchmarking in the French NGS sector.
- Regional Competitive Intelligence : Understand France's position within European genomics markets with country-specific insights on clinical adoption, research trends, and pharmaceutical applications to identify competitive advantages.
- Strategic Market Entry Planning : Access detailed France-focused analysis to develop market entry strategies, identify key stakeholders in French healthcare and research institutions, and assess regulatory requirements for NGS service providers.
- Investment & Partnership Opportunities : Identify high-growth segments within France's NGS market, including clinical diagnostics and pharma R&D, to guide investment allocation and partnership development with French laboratories and healthcare providers.
- Forecast-Driven Business Planning : Leverage France-specific forecasts through 2022 to align product development, resource allocation, and market expansion strategies with anticipated demand growth in genomic sequencing services.
Frequently asked questions
What was the market size of NGS Services in France in 2017?
France's NGS Services Market was valued at $62.7 million in 2017, serving as the baseline for market analysis and growth projections.
What is the forecasted market size for NGS Services in France by 2022?
France's NGS Services Market was forecasted to reach $151.1 million by 2022, reflecting sustained expansion driven by precision medicine adoption.
What is the CAGR for France's NGS Services Market?
France's NGS Services Market demonstrated a compound annual growth rate (CAGR) of 19.2% between 2017 and 2022.
What factors are driving NGS Services growth in France?
France's NGS growth is driven by precision medicine initiatives, government support for genomic research, declining sequencing costs, and regulatory frameworks supporting clinical genomic testing integration.
Which sectors in France are adopting NGS Services most rapidly?
France's oncology, rare disease diagnosis, and infectious disease monitoring sectors are experiencing the most rapid NGS Services adoption among hospitals, diagnostic laboratories, and research institutions.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
